Literature DB >> 12165113

Subclinical hyperthyroidism and atrial fibrillation.

Clark T Sawin1.   

Abstract

Subclinical hyperthyroidism is characterized by a clearly low serum concentration of thyrotropin (TSH) and the absence of obvious symptoms of hyperthyroidism. Whether or not all persons with a low value for serum TSH can be considered subclinically hyperthyroid is uncertain, but the low serum TSH per se is a risk factor for atrial fibrillation and perhaps other cardiovascular disease. Screening all persons, even in the older age groups, for subclinical hyperthyroidism may not be justified in and of itself but such persons would likely be screened for subclinical hypothyroidism and so those with subclinical hyperthyroidism identified. There are no controlled trials that show the benefit of treatment of subclinical hyperthyroidism, thus therapy at present needs to be determined by clinical judgement, aided by monitoring the patient to see if the low serum TSH level persists and assessing the presence or absence of other determinants of therapy such as an elevated serum triiodothyronine (T3) concentration, a multinodular goiter, or the appearance of overt symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165113     DOI: 10.1089/105072502760143881

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Mortality rate of chronically ill geriatric patients with subnormal serum thyrotropin concentration: a 2-yr follow-up study.

Authors:  Andrea Radácsi; Gábor Kovács; Wolfdieter Bernard; Joachim Feldkamp; Franz A Horster; István Szabolcs
Journal:  Endocrine       Date:  2003-07       Impact factor: 3.633

Review 2.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

3.  Subclinical thyroid dysfunction and functional capacity among elderly.

Authors:  Vanessa S Virgini; Liselotte W Wijsman; Nicolas Rodondi; Douglas C Bauer; Patricia M Kearney; Jacobijn Gussekloo; Wendy P J den Elzen; J Wouter Jukema; Rudi G J Westendorp; Ian Ford; David J Stott; Simon P Mooijaart
Journal:  Thyroid       Date:  2013-11-13       Impact factor: 6.568

Review 4.  Subclinical thyroid disorders: the menace of the Trojan horse.

Authors:  L H Duntas
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

5.  Subclinical Thyroid Dysfunction and Frailty Among Older Men.

Authors:  Vanessa S Virgini; Nicolas Rodondi; Peggy M Cawthon; Stephanie Litwack Harrison; Andrew R Hoffman; Eric S Orwoll; Kristine E Ensrud; Douglas C Bauer
Journal:  J Clin Endocrinol Metab       Date:  2015-10-23       Impact factor: 5.958

Review 6.  Thyroid hormones and cardiovascular disease.

Authors:  Avais Jabbar; Alessandro Pingitore; Simon H S Pearce; Azfar Zaman; Giorgio Iervasi; Salman Razvi
Journal:  Nat Rev Cardiol       Date:  2016-11-04       Impact factor: 32.419

7.  Is heart disease a risk factor for low dementia test battery scores in older persons with Down syndrome? Exploratory, pilot study, and commentary.

Authors:  Maire E Percy; Walter J Lukiw
Journal:  Int J Dev Disabil       Date:  2017-04-09

Review 8.  The bidirectional relationship of thyroid disease and atrial fibrillation: Established knowledge and future considerations.

Authors:  Alexandra Bekiaridou; Anastasios Kartas; Dimitrios V Moysidis; Andreas S Papazoglou; Amalia Baroutidou; Anastasios Papanastasiou; George Giannakoulas
Journal:  Rev Endocr Metab Disord       Date:  2022-02-02       Impact factor: 9.306

Review 9.  Cardiac hypertrophy and thyroid hormone signaling.

Authors:  Wolfgang Dillmann
Journal:  Heart Fail Rev       Date:  2009-01-06       Impact factor: 4.214

10.  Thyroid hormones and electrocardiographic parameters: findings from the third national health and nutrition examination survey.

Authors:  Yiyi Zhang; Wendy S Post; Alan Cheng; Elena Blasco-Colmenares; Gordon F Tomaselli; Eliseo Guallar
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.